Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global Healthcare Conferences

ARDSLEY, N.Y.--(BUSINESS WIRE)--

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present at the RBC Capital Markets and the Citi 2013 Global Healthcare conferences in February.

Jane Wasman, President, International and General Counsel, will present at the RBC Capital Markets Healthcare Conference on Tuesday, February 26 at 2:35 pm ET at The New York Palace Hotel in New York. A live audio webcast of the presentation can be accessed under Investor Events in the Investor section of the Acorda website at http://www.acorda.com, or you may use the link:

http://www.veracast.com/webcasts/rbc/healthcare2013/97112243.cfm

Ron Cohen, Acordas President and Chief Executive Officer, will present at the Citi 2013 Global Healthcare Conference on Wednesday, February 27 at 1:30 pm ET at the Hilton New York Hotel in New York. A live audio webcast of the presentation can be accessed under Investor Events in the Investor section of the Acorda website at http://www.acorda.com, or you may use the link:

http://www.veracast.com/webcasts/citigroup/healthcare2013/04308188.cfm

Please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection. Archived versions of these webcasts will be available until March 26 and March 27, 2013, respectively, on the Investors section of http://www.acorda.com.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.

Acorda markets AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.

See more here:
Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global Healthcare Conferences